Hayden E. Klein

The keynote session highlighted trends in COVID-19 and other respiratory illness rates, a bounce back in health care utilization, biosimilar market trends, new product launches, and more.

Michael Burger, senior consultant at Point-of-Care Partners, explains that real-time benefit check lets physicians know how much a drug will cost the patient at the time they're writing the prescription, allowing them to give the patient a treatment they know they can afford.

In this AMCP Market Insights session, panelists discussed best practices and challenges when it comes to prescribing antibody drug conjugates, from the payer, provider, and patient perspectives, based on survey findings.

Among these treatments is an aflibercept product with improved dosing for the patient that is coming up for approval in a few months, explained Jeffrey Casberg, senior director of pharmacy at IPD Analytics.

Advantages to using surrogate vs clinical end points in drug approvals include earlier access, but there can be concerns about the efficacy and end result of the drug, said Yuqian Liu, PharmD, senior director of specialty clinical solutions at Magellan Rx Management.

Pharmacy benefit manager reform is a major trend in state managed care policy, said Adam Colborn, director of government relations at the Academy of Managed Care Pharmacy (AMCP).

Scott Soefje, PharmD, director of pharmacy cancer care at Mayo Clinic, explains the various ways drug dose rounding can reduce waste, reduce costs, and make drug administration more efficient.

Some challenges linking medication adherence to medical cost offsets include the potential of reverse causality, omitted variable bias, how adherence is measured between studies, and the outdated nature of some of the most-cited literature, said Ben Urick, PharmD, PhD, principal health outcomes researcher at Prime Therapeutics.

Recent papers highlight possible role of inflammation in connections between COVID-19, cancer markers.

It's harder for younger children to deal with the complexities of managing type 1 diabetes (T1D), so a delayed diagnosis even by a few years is a big deal, said Kevan Herold, MD, professor of immunobiology and medicine at Yale School of Medicine.

Kimberly Westrich, director of value and access strategy at AmerisourceBergen, previews AMCP 2023 and her preconference session about incorporating value framework assessments into coverage and reimbursement decision-making.

Young children using the t:slim X2 insulin pump with Control-IQ Technology system maintained target glucose levels for 3 hours longer than children using an insulin pump or daily injections with a continuous glucose monitor.

New research suggests older adults with both diabetes and edentulism are more likely to experience worse and faster cognitive decline compared with adults without either condition and adults older in age.

Since 2004, the number of individuals with HIV receiving antiretroviral therapy (ART) has increased 300-fold through the US President’s Emergency Plan for AIDS Relief (PEPFAR).

Body mass index and nadir CD4 count were major factors in SARS-CoV-2 humoral immune repertoire among people with HIV.

Researchers found that only 8 of 18 HIV risk assessment models have been externally validated and show moderate-to-good discrimination ability for HIV infection prediction.

There is clearly an important role for teplizumab to treat type 1 diabetes (T1D) right now, said Kevan Herold, MD, professor of immunobiology and medicine at Yale School of Medicine.

Lee Greenberger, PhD, chief scientific officer of the Leukemia and Lymphoma Society, discusses how the pandemic changed clinical trial enrollment in the leukemia/lymphoma space.

Researchers found that treatment modality was associated with the proportion of youths with type 1 diabetes (T1D) achieving recommended clinical targets.

The study also showed, despite an existing association between discrimination based on sexual orientation and HIV pre-exposure prophylaxis (PrEP) use, increased resilience reduced the effects of such discrimination on PrEP use.

Kevan Herold, MD, professor of immunobiology and medicine at Yale School of Medicine, talks about some insurers' requirement for patients to have a first-degree relative with type 1 diabetes to qualify for coverage of teplizumab.

The 3 companies announced a partnership to provide free, same-day prescription delivery of HIV pre-exposure prophylaxis (PrEP) and antiretroviral medications.

Lee Greenberger, PhD, chief scientific officer of the Leukemia and Lymphoma Society, discusses common questions that patients with leukemia and lymphoma ask about COVID-19 and vaccination.

Eli Lilly announced it will automatically cap out-of-pocket (OOP) costs at $35 at participating retail pharmacies for Americans with commercial insurance using some of its insulin products.

Research found that patients with acute myocardial infarction (AMI) have worse in-hospital clinical outcomes if they also have diabetes, especially type 1.

Jeremy Wigginton, MD, vice president of health quality and innovation at Blue Cross and Blue Shield of Louisiana, explains how the company works with employers to prevent and manage diabetes.

In this interview, Lee Greenberger, PhD, chief scientific officer of the Leukemia and Lymphoma Society, discusses key takeaways from using social media to grow a leukemia and lymphoma registry.

A global case series described a severe form of mpox linked to a 15% mortality rate among people living with HIV and low CD4 counts.

A trial enrolling 97 children newly diagnosed with type 1 diabetes did not meet the primary endpoint of preservation of insulin production by beta cells, but it did show a significant decrease in fasting and clinically relevant reduced serum glucagon.

Researchers looked at trends in insulin usage and expenditure among insured and uninsured populations with diabetes, accounting for how the expansion of Medicaid under the Affordable Care Act may have affected these trends.